CAS: 12321-44-7; Calcitonin (Porcine)

专利信息

专利号:US-4212795-A
优先权日:1978-11-13
标题:Cyclization of peptides
发明人：HUGHES JOHN L; LIU ROBERT C; SEYLER JAY K
权利人:ARMOUR PHARMA
摘要:The synthesis of a disulfide cyclic peptide by preparing an intermediate peptide containing two cysteine moieties, each of which is protected by an n-alkylthio group, or when one of such moieties is in an amino terminal position, this one moiety may be protected by a cysteine group while the other is protected by an n-alkylthio group, and placing such intermediate peptide in a solution substantially free of oxygen and preferably at a pH of from 5 to 10 until rearrangement has taken place, to yield a cyclic disulfide peptide. The disclosure also embraces said intermediate peptides as new compounds and the processes by which they are prepared.

专利号:US-4033940-A
优先权日:1975-11-12
标 题:Cyclization of peptides
发明人：HUGHES JOHN L; SEYLER JAY K; LIU ROBERT C
权利人:ARMOUR PHARMA
摘要:The synthesis of a disulfide cyclic peptide by preparing an intermediate peptide containing an amino terminal cystine residue and a cysteine residue located in a position within the amino acid sequence, to give a desired peptide, and placing such intermediate peptide in a solution substantially free of oxygen at a pH of from about 5 to 10 until rearrangement takes place to yield a cyclic disulfide peptide and to displace a molecule of cysteine from the amino terminal cysteine residue. The disclosure also embraces said intermediate peptides as new compounds and the processes by which they are prepared.

专利号:US-2010062970-A1
优先权日:2006-08-18
标题 :Synthesis of propyl phenoxy ethers and use as delivery agents

专利号:WO-2008022242-A2
优先权日:2006-08-18
标 题:Synthesis of propyl phenoxy ethers and use as delivery agents

专利号:CA-2661018-C
优先权日:2006-08-18
标题 :Synthesis of propyl phenoxy ethers and use as delivery agents

专利号:US-5364840-A
优先权日:1989-12-05
标题:Synthetic calcitonin peptides
发明人：BASAVA CHANNA; HOSTETLER KARL Y
权利人:VICAL INC
摘要:Synthetic hypocalcemic peptides which are superior in biological properties to native calcitonins as clinically useful agents. The peptides comprise analogues of native calcitonins having amino acid additions at the N-terminal position which, either alone or together with substitutions, and deletions at other residues, act to improve potency, prolong duration of the hormonal effect, and increase oral or nasal bioavailability. Methods are provided for the synthesis of these peptides.